351 related articles for article (PubMed ID: 21693461)
41. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.
Schedletzky H; Wiedemann B; Heisig P
J Antimicrob Chemother; 1999 May; 43 Suppl B():31-7. PubMed ID: 10382873
[TBL] [Abstract][Full Text] [Related]
42. Novel Tetrazole-Based Antimicrobial Agents Targeting Clinical Bacteria Strains: Exploring the Inhibition of
Roszkowski P; Szymańska-Majchrzak J; Koliński M; Kmiecik S; Wrzosek M; Struga M; Szulczyk D
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008805
[TBL] [Abstract][Full Text] [Related]
43. Synergistic Effects of Thiosemicarbazides with Clinical Drugs against
Chudzik-Rząd B; Malm A; Trotsko N; Wujec M; Plech T; Paneth A
Molecules; 2020 May; 25(10):. PubMed ID: 32422899
[TBL] [Abstract][Full Text] [Related]
44. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.
Zhao X; Quinn B; Kerns R; Drlica K
J Antimicrob Chemother; 2006 Dec; 58(6):1283-6. PubMed ID: 17003060
[TBL] [Abstract][Full Text] [Related]
45. Mechanism of inhibition of DNA gyrase by ES-1273, a novel DNA gyrase inhibitor.
Oyamada Y; Yamagishi J; Kihara T; Yoshida H; Wachi M; Ito H
Microbiol Immunol; 2007; 51(10):977-84. PubMed ID: 17951987
[TBL] [Abstract][Full Text] [Related]
46. Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV.
Gibson EG; Oviatt AA; Cacho M; Neuman KC; Chan PF; Osheroff N
Biochemistry; 2019 Nov; 58(44):4447-4455. PubMed ID: 31617352
[TBL] [Abstract][Full Text] [Related]
47. Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase.
Bellon S; Parsons JD; Wei Y; Hayakawa K; Swenson LL; Charifson PS; Lippke JA; Aldape R; Gross CH
Antimicrob Agents Chemother; 2004 May; 48(5):1856-64. PubMed ID: 15105144
[TBL] [Abstract][Full Text] [Related]
48. Synthesis of novel 2-aminobenzothiazole derivatives as potential antimicrobial agents with dual DNA gyrase/topoisomerase IV inhibition.
Ismail MMF; Abdulwahab HG; Nossier ES; El Menofy NG; Abdelkhalek BA
Bioorg Chem; 2020 Jan; 94():103437. PubMed ID: 31812260
[TBL] [Abstract][Full Text] [Related]
49. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV of Enterococcus faecalis.
Onodera Y; Okuda J; Tanaka M; Sato K
Antimicrob Agents Chemother; 2002 Jun; 46(6):1800-4. PubMed ID: 12019093
[TBL] [Abstract][Full Text] [Related]
50. Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase.
Gibson EG; Bax B; Chan PF; Osheroff N
ACS Infect Dis; 2019 Apr; 5(4):570-581. PubMed ID: 30757898
[TBL] [Abstract][Full Text] [Related]
51. Isolation and quantitation of topoisomerase complexes accumulated on Escherichia coli chromosomal DNA.
Aedo S; Tse-Dinh YC
Antimicrob Agents Chemother; 2012 Nov; 56(11):5458-64. PubMed ID: 22869559
[TBL] [Abstract][Full Text] [Related]
52. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus.
Tanaka M; Onodera Y; Uchida Y; Sato K; Hayakawa I
Antimicrob Agents Chemother; 1997 Nov; 41(11):2362-6. PubMed ID: 9371334
[TBL] [Abstract][Full Text] [Related]
53. Altering gene expression by aminocoumarins: the role of DNA supercoiling in Staphylococcus aureus.
Schröder W; Bernhardt J; Marincola G; Klein-Hitpass L; Herbig A; Krupp G; Nieselt K; Wolz C
BMC Genomics; 2014 Apr; 15():291. PubMed ID: 24734910
[TBL] [Abstract][Full Text] [Related]
54. Alteration of Escherichia coli topoisomerase IV to novobiocin resistance.
Hardy CD; Cozzarelli NR
Antimicrob Agents Chemother; 2003 Mar; 47(3):941-7. PubMed ID: 12604525
[TBL] [Abstract][Full Text] [Related]
55. Synthesis, Antimicrobial Activity and Molecular Docking of Novel Thiourea Derivatives Tagged with Thiadiazole, Imidazole and Triazine Moieties as Potential DNA Gyrase and Topoisomerase IV Inhibitors.
Hashem HE; Amr AEE; Nossier ES; Elsayed EA; Azmy EM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32549386
[TBL] [Abstract][Full Text] [Related]
56. Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.
Lu T; Zhao X; Li X; Drlica-Wagner A; Wang JY; Domagala J; Drlica K
Antimicrob Agents Chemother; 2001 Oct; 45(10):2703-9. PubMed ID: 11557458
[TBL] [Abstract][Full Text] [Related]
57. DNA cleavage activities of Staphylococcus aureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones.
Saiki AY; Shen LL; Chen CM; Baranowski J; Lerner CG
Antimicrob Agents Chemother; 1999 Jul; 43(7):1574-7. PubMed ID: 10390205
[TBL] [Abstract][Full Text] [Related]
58. Thiazolidine-2,4-dione-linked ciprofloxacin derivatives with broad-spectrum antibacterial, MRSA and topoisomerase inhibitory activities.
Aziz HA; El-Saghier AMM; Badr M; Abuo-Rahma GEA; Shoman ME
Mol Divers; 2022 Jun; 26(3):1743-1759. PubMed ID: 34455532
[TBL] [Abstract][Full Text] [Related]
59. Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors.
D'Atanasio N; Capezzone de Joannon A; Di Sante L; Mangano G; Ombrato R; Vitiello M; Bartella C; Magarò G; Prati F; Milanese C; Vignaroli C; Di Giorgio FP; Tongiani S
PLoS One; 2020; 15(2):e0228509. PubMed ID: 32074119
[TBL] [Abstract][Full Text] [Related]
60. New potent ciprofloxacin-uracil conjugates as DNA gyrase and topoisomerase IV inhibitors against methicillin-resistant Staphylococcus aureus.
Samir M; Ramadan M; Abdelrahman MH; Elbastawesy MAI; Halby HM; Abdel-Aziz M; Abuo-Rahma GEA
Bioorg Med Chem; 2022 Nov; 73():117004. PubMed ID: 36148773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
